Zolbetuximab Is a Promising Therapy for HER2-Negative Gastric Cancer
XTalks
JULY 17, 2023
Gastric cancer, which originates in the stomach, ranks among the most common cancers globally. Gastroesophageal junction (GEJ) adenocarcinoma, a cancer originating at the junction where the esophagus meets the stomach, carries low five-year survival rates for metastatic stage patients.
Let's personalize your content